External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APAO 2024

-
Coming soon
03:00 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Faricimab▼ Treatment Outcomes With Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
Chang A, Lim J, Singer M, Idowu O, Hill L, Gibson K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:04 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Biomarkers for Vascular Stability Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition With Faricimab▼ in Phase 3 Trials in DME
Szeto S, Tan C, Maunz A, Patel K, von Schulthess E, Wang T, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:08 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, Durability and Safety of Faricimab▼ in nAMD: 48-Week Results From the China Subpopulation of Phase 3 LUCERNE
Chen Y, Zhang M, Sun D, Li S, Patel S, Liu R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:12 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Li X, Sun X, Jiang Q, Idowu O, Tang Y, Liu R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:26 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials
Tan A, Singer M, Hill L, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:08 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Results From the Portal 5-Year Subgroup Analysis
Hwang DK, Cheung G, Howard J, Nielsen J, Singh N, Cavichini Cordeiro M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:32 PM
Duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): Results From the Phase 3 Pagoda and Pavilion Trials
Sagong M, Emanuelli A, Holekamp N, Heinrich D, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:40 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Eyes With Neovascular Age-Related Macular Degeneration
Chaikitmongkol V, Khanani A, Margaron P, Souverain A, Patel S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:44 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Macular Leakage in DME With Faricimab▼ vs Aflibercept
Tan G, Goldberg R, Nudleman E, Sivaprasad S, Wang T, Mar F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar